XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...